Research & development decreased 7.4%
Research & development changed -7.4% from the comparable as-filed period. The change ranks at the 19th percentile of 31 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed -7.4% from the comparable as-filed period. The change ranks at the 19th percentile of 31 prior comparable changes.
Net income changed +28.3% from the comparable as-filed period. The change ranks at the 48th percentile of 31 prior comparable changes.
Operating income changed +37.9% from the comparable as-filed period. The change ranks at the 58th percentile of 31 prior comparable changes.
Operating margin changed +873 basis points from the comparable as-filed period. The change ranks at the 23th percentile of 31 prior comparable changes.
Stock-based compensation changed +25.4% from the comparable as-filed period. The change ranks at the 36th percentile of 28 prior comparable changes.
Gross profit changed +16.5% from the comparable as-filed period. The change ranks at the 29th percentile of 31 prior comparable changes.
Revenue changed +17.7% from the comparable as-filed period. The change ranks at the 26th percentile of 31 prior comparable changes.
Cash & equivalents changed +0.7% from the comparable as-filed period. The change ranks at the 0th percentile of 57 prior comparable changes.
Gross margin changed -65 basis points from the comparable as-filed period. The change ranks at the 13th percentile of 31 prior comparable changes.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.